Performance characteristics of next-generation sequencing in clinical mutation detection of colorectal cancers

Modern Pathology

Volumn 28, Issue 10, 2015, Pages 1390-1399

  Haley, Lisa ^a   Tseng, Li Hui ^a,b   Zheng, Gang ^a   Dudley, Jonathan ^a,c   Anderson, Derek A ^a   Azad, Nilofer S ^a   Gocke, Christopher D ^a   Eshleman, James R ^a   Lin, Ming Tseh ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; K RAS PROTEIN; NRAS PROTEIN; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE CATALYTIC SUBUNIT ALPHA; PROTEIN; UNCLASSIFIED DRUG; BRAF PROTEIN, HUMAN; GUANOSINE TRIPHOSPHATASE; KRAS PROTEIN, HUMAN; MEMBRANE PROTEIN; NRAS PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN; PROTEIN P21;

ADENOMA; ALLELE; ARTICLE; CANCER DIAGNOSIS; CANCER RESISTANCE; CODON; COLORECTAL CANCER; CONTROLLED STUDY; EXON; GENE FREQUENCY; GENE MUTATION; HUMAN; HUMAN TISSUE; INVASIVE CARCINOMA; INVASIVE NEUROENDOCRINE CARCINOMA; MAJOR CLINICAL STUDY; NEXT GENERATION SEQUENCING; PREDICTION; PRIORITY JOURNAL; QUALITY CONTROL; RETROSPECTIVE STUDY; COLORECTAL TUMOR; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE; GENETICS; HIGH THROUGHPUT SEQUENCING; PATHOLOGY; PROCEDURES;

COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, NEOPLASM; GTP PHOSPHOHYDROLASES; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MEMBRANE PROTEINS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS P21(RAS); RETROSPECTIVE STUDIES;

EID: 84942983135     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2015.86     Document Type: Article

References (41)

1. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127-137.
2. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-345.
3. Van Cutsem E, Peeters M, Siena S et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007;25:1658-1664.
4. Karapetis CS, Khambata-Ford S, Jonker DJ et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359:1757-1765.
5. De Roock W, Claes B, Bernasconi D et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010;11:753-762.
6. Douillard JY, Oliner KS, Siena S et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013;369:1023-1034.
7. Allegra CJ, Jessup JM, Somerfield MR et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009; 27:2091-2096.
8. Peeters M, Oliner KS, Parker A et al. Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer. Clin Cancer Res 2013;19: 1902-1912.
9. Sorich MJ, Wiese MD, Rowland A et al. Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. Ann Oncol 2015;26:13-12.
10. Di Nicolantonio F, Martini M, Molinari F et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008;26:5705-5712.
11. Cathomas G. PIK3CA in colorectal cancer. Front Oncol 2014;4:35.
12. Wong NA, Gonzalez D, Salto-Tellez M et al. RAS testing of colorectal carcinoma - A guidance document from the Association of Clinical Pathologists Molecular Pathology and Diagnostics Group. J Clin Pathol 2014; 67:751-757.
13. Dienstmann R, Rodon J, Barretina J et al. Genomic medicine frontier in human solid tumors: prospects and challenges. J Clin Oncol 2013;31:1874-1884.
14. Deeb KK, Sram JP, Gao H et al. Multigene assays in metastatic colorectal cancer. J Natl Compr Canc Netw 2013;11:S9-17.
15. Ciardiello F, Normanno N, Maiello E et al. Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial. Ann Oncol 2014;25:1756-1761.
16. Lin MT, Mosier SL, Thiess M et al. Clinical validation of KRAS, BRAF, and EGFR mutation detection using next-generation sequencing. Am J Clin Pathol 2014;141:856-866.
17. Lin MT, Tseng LH, Rich RG et al. Δ-PCR, a simple method to detect translocations and insertion/deletion mutations. J Mol Diagn 2011;13:85-92.
18. Dudley JC, Gurda GT, Tseng LH et al. Tumor cellularity as a quality assurance measure for accurate clinical detection of BRAF mutations in melanoma. Mol Diagn Ther 2014;18:409-418.
19. Wan PT, Garnett MJ, Roe SM et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004;116:855-867.
20. Heidorn SJ, Milagre C, Whittaker S et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 2010;140:209-221.
21. Frampton GM, Fichtenholtz A, Otto GA et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 2013;31:1023-1031.
22. Dudley J, Tseng LH, Rooper L et al. Challenges posed to pathologists in the detection of KRAS mutations in colorectal cancers. Arch Pathol Lab Med 2015;139: 211-218.
23. Anderson S, Bloom KJ, Vallera DU et al. Multisite analytic performance studies of a real-time polymerase chain reaction assay for the detection of BRAF V600E mutations in formalin-fixed, paraffin-embedded tissue specimens of malignant melanoma. Arch Pathol Lab Med 2012;136:1385-1391.
24. Halait H, Demartin K, Shah S et al. Analytical performance of a real-time PCR-based assay for V600 mutations in the BRAF gene, used as the companion diagnostic test for the novel BRAF inhibitor vemurafenib in metastatic melanoma. Diagn Mol Pathol 2012;21:1-8.
25. Harbison CT, Horak CE, Ledeine JM et al. Validation of companion diagnostic for detection of mutations in codons 12 and 13 of the KRAS gene in patients with metastatic colorectal cancer: analysis of the NCIC CTG CO.17 trial. Arch Pathol Lab Med 2013;137:820-827.
26. Paik PK, Arcila ME, Fara M et al. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol 2011;29:2046-2051.
27. Sen B, Peng S, Tang X et al. Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib. Sci Transl Med 2012;4:136ra70.
28. Huang L, Liu Z, Deng D et al. Anti-epidermal growth factor receptor monoclonal antibody-based therapy for metastatic colorectal cancer: a meta-analysis of the effect of PIK3CA mutations in KRAS wild-type patients. Arch Med Sci 2014;10:1-9.
29. Mao C, Yang ZY, Hu XF et al. PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis. Ann Oncol 2012;23:1518-1525.
30. Iacopetta B. Are there two sides to colorectal cancer? Int J Cancer 2002;101:403-408.
31. Missiaglia E, Jacobs B, D'Ario G et al. Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. Ann Oncol 2014;25: 1995-2001.
32. Loupakis F, Yang D, Yau L et al. Primary tumor location as a prognostic factor in metastatic colorectal cancer. J Natl Cancer Inst 2015;107:dju427.
33. Roth AD, Tejpar S, Delorenzi M et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 2010;28:466-474.
34. Yamauchi M, Morikawa T, Kuchiba A et al. Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. Gut 2012;61:847-854.
35. Gonsalves WI, Mahoney MR, Sargent DJ et al. Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147. J Natl Cancer Inst 2014;106:dju106.
36. Rosty C, Young JP, Walsh MD et al. Colorectal carcinomas with KRAS mutation are associated with distinctive morphological and molecular features. Mod Pathol 2013;26:825-834.
37. Brule SY, Jonker DJ, Karapetis CS et al. Location of colon cancer (right-sided [RC] versus left-sided [LC]) as a predictor of benefit from cetuximab (CET): NCIC CTG CO.17. J Clin Oncol 2013;31:3528.
38. Chen G, Dudley J, Tseng LH et al. Lymph node metastases of melanoma: challenges for BRAF mutation detection. Hum Pathol 2015;46:113-119.
39. Diaz LA Jr, Williams RT, Wu J et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 2012;486: 537-540.
40. Misale S, Yaeger R, Hobor S et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012;486: 532-536.
41. Jones S, Chen WD, Parmigiani G et al. Comparative lesion sequencing provides insights into tumor evolution. Proc Natl Acad Sci US A 2008;105:4283-4288.